Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.59 |
| ▸ | CTSS | P25774 | 8/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245652 | 1.00 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12965802 | 1.00 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5532831 | 0.87 | CTSK (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18925259 | 0.87 | CTSK (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18892598 | 0.87 | CTSK (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23016033 | 0.85 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12965804 | 0.85 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15435539 | 0.85 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1688825 | 0.85 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL318796 | 0.85 | CTSK (0.64) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| EP-3490977-B1 | CYCLOBUTANE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED POTASSIUM CHANNELS | AUTIFONY THERAPEUTICS LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-2150269-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | CTSK 193/4885CTSS 287/4885CYP1A2 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.